Kanama Diyatezine Yaklaşım
Synopsis
Bleeding diathesis is a complex condition that requires a detailed clinical history, physical examination, and laboratory testing for the recognition of hemostatic disorders. In the history, the onset, duration, site of bleeding, response to surgical and dental procedures, use of medications or herbal products, and family history are evaluated to determine whether the hemostatic defect is me inherited or acquired. Superficial mucosal bleeding and petechiae indicate primary hemostasis (platelet) disorders, whereas deep tissue hematomas and hemarthroses point to secondary hemostasis (coagulation factor) problems. Laboratory evaluation begins with initial screening tests including complete blood count, peripheral blood smear, prothrombin time (PT), and activated partial thromboplastin time (aPTT). An isolated prolongation of PT indicates extrinsic pathway defects such as factor VII deficiency; an isolated prolongation of aPTT indicates intrinsic pathway disorders like hemophilia A, B, C, or factor XII deficiency; and prolongation of both suggests common pathway factor deficiencies, vitamin K deficiency, liver disease, or disseminated intravascular coagulation (DIC). In patients with a persistent history of bleeding despite normal initial screening tests, conditions such as von Willebrand disease, platelet function disorders, and factor XIII deficiency must be investigated using specialized tests such as PFA-100, aggregation assays, and specific factor levels.
References
Girolami A, Luzzatto G, Varvarikis C, et al. Main clinical manifestations of a bleeding diathesis: an often disregarded aspect of medical and surgical history taking. Haemophilia 2005; 11:193.
Laffan M, Brown SA, Collins PW. The diagnosis of von Willebrand disease: aguideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004;10:199-217.
Mannucci PM; Mannucci, Pier Mannuccio. Treatment of von Willebrand’s Disease.N. Engl J Med 2004;35:683-94. 10. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67: 395-424.
Rodeghiero F, Kadir RA, Tosetto A, James PD. Relevance of quantitative assessment of bleeding in haemorrhagic disorders. Haemophilia 2008; 14 Suppl 3:68.
James AH. Von Willebrand disease. Obstet Gynecol Surv 2006; 61:136.
Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, , Salzman EW. Hemostasis and thrombosis: Basic principles and clinical practice. 3rd ed. Philadelphia: JP Lippicort Co. 1993:3-18.
Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thionopyridine derivatives, an warfarin in elderly patients following acute miyocardial infarction. Arch Intern Med 2005;165:784.
Schafer AI. Hemorrhagic disorders: Disseminated intravascular coagulation, liver failure, and vitamin K deficiency. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 181.
Karim M, Bereczky Z, Cohan N, Muszbek L. Semin Thromb Hemost 2009;35:426- 38.
Wallin R, Schurgers L, Wajih N. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb Res. 2008;122: 411.
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008.
O'Brien SH, Ritchey AK, Ragni MV. Combined clotting factor deficiencies: experience at a single hemophilia treatment center. Haemophilia 2007; 13:26.
Gurney D. Platelet function testing: from routine to specialist testing. Br J Biomed Sci 2016; 73:10.